Price: FREE for members and non-members
Session recorded on July 26, 2022
Speaker: Vickram Tejwani, MD
Description: Chronic obstructive pulmonary disease (COPD) therapies have been fairly limited for several decades, however this may be due to approaching the heterogenous disease of COPD as a single homogenous disease. A better understanding of phenotypes may allow identification of treatable traits and a precision medicine paradigm for COPD. This webinar will help health care providers to be able to phenotype COPD to provide targeted therapy if indicated and keep in mind for future focused clinical trials.
Viewers can earn credit by completing the posttest questions.
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Providers
Upon completion of this activity learners should be able to:
- Discuss the evolving definition of COPD
- Diagnose and identify the established COPD phenotypes
- Assess for treatable traits in COPD
All relevant finaicial relationships have been mitigated.
Michael Blaiss, MD, FACAAI Planner
Disclosures: Consultant: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
Vickram Tejawani, MD, FACAAI Speaker
Disclosures: No relevant financial relationships to disclose.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance